```json
{
"content": [
{
"type": "paragraph",
"content": "Sodium Valproate, a broad-spectrum anticonvulsant and mood-stabilizing drug, remains a cornerstone in the management of epilepsy, bipolar disorder, and migraine prevention. Its Sodium Valproate market size is estimated at USD 1.2 billion in 2026, reflecting steady industry expansion driven by rising neurological disorders and aging populations. This market forecast underscores its critical role in global healthcare systems, with regulatory dynamics and therapeutic innovation shaping its trajectory."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Epilepsy", "Bipolar Disorder", "Migraine Prevention"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[450, 470, 490, 510, 530, 550, 570, 590, 610, 630, 650, 670, 690], // Epilepsy
[250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370], // Bipolar Disorder
[150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270] // Migraine Prevention
]
}
},
{
"type": "paragraph",
"content": "The Sodium Valproate market is projected to grow at a CAGR of 4.5% from 2026 to 2033, fueled by macro drivers such as the rising prevalence of epilepsy (1% of the global population) and increased adoption of generic formulations post-patent expirations. Key forces reshaping the industry include regulatory scrutiny over teratogenic risks, spurring R&D in safer alternatives, and digitization in patient monitoring for chronic neurological conditions. North America dominates the market due to high treatment rates, while Asia-Pacific is the fastest-growing region, propelled by expanding healthcare infrastructure and rising disposable incomes."
}
]
}
```
